1453. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.
作者: Andreas Baumbach.;Niels van Royen.;Ignacio J Amat-Santos.;Martin Hudec.;Matjaz Bunc.;Alexander Ijsselmuiden.;Peep Laanmets.;Daniel Unic.;Bela Merkely.;Renicus S Hermanides.;Vlasis Ninios.;Marcin Protasiewicz.;Benno J W M Rensing.;Pedro L Martin.;Fausto Feres.;Manuel De Sousa Almeida.;Eric van Belle.;Axel Linke.;Alfonso Ielasi.;Matteo Montorfano.;Mark Webster.;Konstantinos Toutouzas.;Emmanuel Teiger.;Francesco Bedogni.;Michiel Voskuil.;Manuel Pan.;Oskar Angerås.;Won-Keun Kim.;Jürgen Rothe.;Ivica Kristić.;Vicente Peral.;Scot Garg.;Hesham Elzomor.;Akihiro Tobe.;Marie-Claude Morice.;Yoshinobu Onuma.;Osama Soliman.;Patrick W Serruys.; .
来源: Lancet. 2024年403卷10445期2695-2708页
Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA).
1456. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
作者: Alexa B Kimball.;Gregor B E Jemec.;Christopher J Sayed.;Joslyn S Kirby.;Errol Prens.;John R Ingram.;Amit Garg.;Alice B Gottlieb.;Jacek C Szepietowski.;Falk G Bechara.;Evangelos J Giamarellos-Bourboulis.;Hideki Fujita.;Robert Rolleri.;Paulatsya Joshi.;Pratiksha Dokhe.;Edward Muller.;Luke Peterson.;Cynthia Madden.;Muhammad Bari.;Christos C Zouboulis.
来源: Lancet. 2024年403卷10443期2504-2519页
Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa.
1458. Societal implications of the Dobbs v Jackson Women's Health Organization decision.
作者: Claire D Brindis.;Melissa H Laitner.;Ellen Wright Clayton.;Susan C Scrimshaw.;Barbara J Grosz.;Lisa A Simpson.;Sara Rosenbaum.;Corale L Brierley.;Melissa A Simon.;Yvette Roubideaux.;Bruce N Calonge.;Paula A Johnson.;Laura DeStefano.;Ashley Bear.;Kavita S Arora.;Victor J Dzau.
来源: Lancet. 2024年403卷10445期2751-2754页
On June 24, 2022, the US Supreme Court's decision in Dobbs v Jackson Women's Health Organization marked the removal of the constitutional right to abortion in the USA, introducing a complex ethical and legal landscape for patients and providers. This shift has had immediate health and equity repercussions, but it is also crucial to examine the broader impacts on states, health-care systems, and society as a whole. Restrictions on abortion access extend beyond immediate reproductive care concerns, necessitating a comprehensive understanding of the ruling's consequences across micro and macro levels. To mitigate potential harm, it is imperative to establish a research agenda that informs policy making and ensures effective long-term monitoring and reporting, addressing both immediate and future impacts.
1459. Health-care workforce implications of the Dobbs v Jackson Women's Health Organization decision.
作者: Claire D Brindis.;Melissa H Laitner.;Ellen Wright Clayton.;Susan C Scrimshaw.;Barbara J Grosz.;Lisa A Simpson.;Sara Rosenbaum.;Corale L Brierley.;Melissa A Simon.;Yvette Roubideaux.;Bruce N Calonge.;Paula A Johnson.;Laura DeStefano.;Ashley Bear.;Kavita S Arora.;Victor J Dzau.
来源: Lancet. 2024年403卷10445期2747-2750页
The Dobbs v Jackson Women's Health Organization Supreme Court decision, which revoked the constitutional right to abortion in the USA, has impacted the national medical workforce. Impacts vary across states, but providers in states with restrictive abortion laws now must contend with evolving legal and ethical challenges that have the potential to affect workforce safety, mental health, education, and training opportunities, in addition to having serious impacts on patient health and far-reaching societal consequences. Moreover, Dobbs has consequences on almost every facet of the medical workforce, including on physicians, nurses, pharmacists, and others who work within the health-care system. Comprehensive research is urgently needed to understand the wide-ranging implications of Dobbs on the medical workforce, including legal, ethical, clinical, and psychological dimensions, to inform evidence-based policies and standards of care in abortion-restrictive settings. Lessons from the USA might also have global relevance for countries facing similar restrictions on reproductive care.
|